Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
379 studies found for:    "HIV Seronegativity" [CONDITION]
Show Display Options
Rank Status Study
21 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
22 Completed Carotid Artery Thickness in HIV Infected and Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity;   Atherosclerosis
Intervention:
23 Completed HIV Incidence and Participation Retention in Pune, India
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
24 Terminated Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Drug: Tenofovir DF
25 Completed Long-Term Effects of HIV Exposure and Infection in Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
26 Completed Botanical/Drug Interactions in HIV: Glucuronidation
Condition: HIV Seronegativity
Intervention: Drug: silymarin
27 Completed Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
28 Recruiting Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
Conditions: PrEP Uptake;   HIV Seronegativity
Intervention: Behavioral: Informed Risk Score
29 Completed A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of  rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
30 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
31 Completed The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Conditions: HIV Infections;   HIV Seronegativity;   Lipodystrophy
Interventions: Drug: Pravastatin sodium;   Drug: Simvastatin;   Drug: Atorvastatin calcium;   Drug: Nelfinavir mesylate;   Drug: Efavirenz
32 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
33 Completed Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Conditions: HIV Infections;   Vitamin A Deficiency;   HIV Seronegativity
Intervention: Drug: Vitamin A
34 Completed Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
35 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
36 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
37 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
38 Completed A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205)
39 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
40 Completed Peer Mentors for Adolescents in HIV Affected Families
Conditions: Adolescent Behavior;   Health Behavior;   HIV Seronegativity
Intervention: Behavioral: Peer mentoring program

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years